Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 1/2024

13-11-2023 | Pregnancy Cholestasis | Review Article

Intrahepatic cholestasis of pregnancy: insights into pathogenesis and advances in omics studies

Authors: Mi Tang, Liling Xiong, Jianghui Cai, Jinzhu Fu, Hong Liu, Ying Ye, Li Yang, ShaSha Xing, Xiao Yang

Published in: Hepatology International | Issue 1/2024

Login to get access

Abstract

Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-specific liver disease. It is characterized by pruritus, abnormal liver function and elevated total bile acid (TBA) levels, increasing the risk of maternal and fetal adverse outcomes. Its etiology remains poorly elucidated. Over the years, various omics techniques, including metabolomics, microbiome, genomics, etc., have emerged with the advancement of bioinformatics, providing a new direction for exploring the pathogenesis, diagnosis and treatment of ICP. In this review, we first summarize the role of bile acids and related components in the pathogenesis of ICP and then further illustrate the results of omics studies.
Literature
1.
Lee RH, Mara G, Metz TD, Pettker CM. Society for maternal-fetal medicine consult series #53: intrahepatic cholestasis of pregnancy: replaces consult #13, April 2011. Am J Obstet Gynecol. 2021;224:B2-b9PubMedCrossRef
2.
Wikström Shemer EA, Stephansson O, Thuresson M, Thorsell M, Ludvigsson JF, Marschall HU. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: a population-based cohort study. J Hepatol. 2015;63:456–461PubMedCrossRef
3.
4.
Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393:899–909PubMedPubMedCentralCrossRef
5.
Cheong-See F, Schuit E, Arroyo-Manzano D, Khalil A, Barrett J, Joseph KS, et al. Prospective risk of stillbirth and neonatal complications in twin pregnancies: systematic review and meta-analysis. BMJ. 2016;354: i4353PubMedPubMedCentralCrossRef
6.
Sepúlveda WH, González C, Cruz MA, Rudolph MI. Vasoconstrictive effect of bile acids on isolated human placental chorionic veins. Eur J Obstet Gynecol Reprod Biol. 1991;42:211–215PubMedCrossRef
7.
Vasavan T, Deepak S, Jayawardane IA, Lucchini M, Martin C, Geenes V, et al. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations. J Hepatol. 2021;74:1087–1096PubMedPubMedCentralCrossRef
8.
Fan X, Zhou Q, Zeng S, Zhou J, Peng Q, Zhang M, et al. Impaired fetal myocardial deformation in intrahepatic cholestasis of pregnancy. J Ultrasound Med. 2014;33:1171–1177PubMedCrossRef
9.
Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004;40:467–474PubMedCrossRef
10.
Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology. 2014;59:1482–1491PubMedCrossRef
11.
Mei Y, Lin Y, Luo D, Gao L, He L. Perinatal outcomes in intrahepatic cholestasis of pregnancy with monochorionic diamniotic twin pregnancy. BMC Pregnancy Childbirth. 2018;18:291PubMedPubMedCentralCrossRef
12.
Song F, Chen Y, Chen L, Li H, Cheng X, Wu W. Association of elevated maternal serum total bile acids with low birth weight and intrauterine fetal growth restriction. JAMA Netw Open. 2021;4: e2117409PubMedPubMedCentralCrossRef
13.
Reyes H, Radrigan ME, Gonzalez MC, Latorre R, Ribalta J, Segovia N, et al. Steatorrhea in patients with intrahepatic cholestasis of pregnancy. Gastroenterology. 1987;93:584–590PubMedCrossRef
14.
Maldonado M, Alhousseini A, Awadalla M, Idler J, Welch R, Puder K, et al. Intrahepatic cholestasis of pregnancy leading to severe vitamin K deficiency and coagulopathy. Case Rep Obstet Gynecol. 2017;2017:5646247PubMedPubMedCentral
15.
Expert consensus on the diagnosis and treatment of intrahepatic cholestasis (2021 edition). Zhonghua Gan Zang Bing Za Zhi 2022;30:137–146.
16.
17.
18.
Anzivino C, Odoardi MR, Meschiari E, Baldelli E, Facchinetti F, Neri I, et al. ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. Dig Liver Dis. 2013;45:226–232PubMedCrossRef
19.
Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet. 1999;353:210–211PubMedCrossRef
20.
Kawakita T, Parikh LI, Ramsey PS, Huang CC, Zeymo A, Fernandez M, et al. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol. 2015;213(570):e571-578
21.
Meier Y, Zodan T, Lang C, Zimmermann R, Kullak-Ublick GA, Meier PJ, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol. 2008;14:38–45PubMedPubMedCentralCrossRef
22.
23.
Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K. Molecular physiology of bile acid signaling in health, disease, and aging. Physiol Rev. 2021;101:683–731PubMedCrossRef
24.
Müllenbach R, Bennett A, Tetlow N, Patel N, Hamilton G, Cheng F, et al. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut. 2005;54:829–834PubMedPubMedCentralCrossRef
25.
Song X, Vasilenko A, Chen Y, Valanejad L, Verma R, Yan B, et al. Transcriptional dynamics of bile salt export pump during pregnancy: mechanisms and implications in intrahepatic cholestasis of pregnancy. Hepatology. 2014;60:1993–2007PubMedCrossRef
26.
Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJ. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol. 2006;44:1150–1157PubMedCrossRef
27.
Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000;118:422–430PubMedCrossRef
28.
Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 1997;113:255–264PubMedCrossRef
29.
Abu-Hayyeh S, Martinez-Becerra P, Sheikh Abdul Kadir SH, Selden C, Romero MR, Rees M, et al. Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites. J Biol Chem. 2010;285:16504–16512PubMedPubMedCentralCrossRef
30.
Raz Y, Lavie A, Vered Y, Goldiner I, Skornick-Rapaport A, Landsberg Asher Y, et al. Severe intrahepatic cholestasis of pregnancy is a risk factor for preeclampsia in singleton and twin pregnancies. Am J Obstet Gynecol. 2015;213(395):e391-398
31.
Brites D, Rodrigues CM, van Zeller H, Brito A, Silva R. Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: Portugal. Eur J Obstet Gynecol Reprod Biol. 1998;80:31–38PubMedCrossRef
32.
33.
Lunzer M, Barnes P, Byth K, O’Halloran M. Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis. Gastroenterology. 1986;91:825–829PubMedCrossRef
34.
Jendryczko A. Tomala J [Bile acids from blood serum of women during normal pregnancy]. Ginekol Pol. 1994;65:230–233PubMed
35.
Pascual MJ, Serrano MA, El-Mir MY, Macias RI, Jiménez F, Marin JJ. Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clin Sci (Lond). 2002;102:587–593PubMedCrossRef
36.
Ontsouka E, Schroeder M, Ok L, Vaillancourt C, Stroka D, Albrecht C. The placenta-a new source of bile acids during healthy pregnancy? first results of a gene expression study in humans and mice. Int J Mol Sci. 2023;24:9511PubMedPubMedCentralCrossRef
37.
Colombo C, Roda A, Roda E, Buscaglia M, dell’Agnola CA, Filippetti P, et al. Correlation between fetal and maternal serum bile acid concentrations. Pediatr Res. 1985;19:227–231PubMedCrossRef
38.
Délèze G, Paumgartner G, Karlaganis G, Giger W, Reinhard M, Sidiropoulos D. Bile acid pattern in human amniotic fluid. Eur J Clin Invest. 1978;8:41–45PubMedCrossRef
39.
Heikkinen J, Mäentausta O, Tuimala R, Ylöstalo P, Jänne O. Amniotic fluid bile acids in normal and pathologic pregnancy. Obstet Gynecol. 1980;56:60–64PubMed
40.
Collier AC, Ganley NA, Tingle MD, Blumenstein M, Marvin KW, Paxton JW, et al. UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol. 2002;63:409–419PubMedCrossRef
41.
He D, Meloche CA, Dumas NA, Frost AR, Falany CN. Different subcellular localization of sulphotransferase 2B1b in human placenta and prostate. Biochem J. 2004;379:533–540PubMedPubMedCentralCrossRef
42.
Patel P, Weerasekera N, Hitchins M, Boyd CA, Johnston DG, Williamson C. Semi quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C, OATP-D, OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. Placenta. 2003;24:39–44PubMedCrossRef
43.
Lofthouse EM, Torrens C, Manousopoulou A, Nahar M, Cleal JK, O’Kelly IM, et al. Ursodeoxycholic acid inhibits uptake and vasoconstrictor effects of taurocholate in human placenta. Faseb j. 2019;33:8211–8220PubMedPubMedCentralCrossRef
44.
Ontsouka E, Epstein A, Kallol S, Zaugg J, Baumann M, Schneider H, et al. Placental expression of bile acid transporters in intrahepatic cholestasis of pregnancy. Int J Mol Sci. 2021;22:10434PubMedPubMedCentralCrossRef
45.
Azzaroli F, Mennone A, Feletti V, Simoni P, Baglivo E, Montagnani M, et al. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment Pharmacol Ther. 2007;26:1139–1146PubMedCrossRef
46.
Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007;48:2664–2672PubMedCrossRef
47.
Li H, Chen F, Shang Q, Pan L, Shneider BL, Chiang JY, et al. FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade. Am J Physiol Gastrointest Liver Physiol. 2005;288:G60-66PubMedCrossRef
48.
Keitel V, Spomer L, Marin JJ, Williamson C, Geenes V, Kubitz R, et al. Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta. 2013;34:810–816PubMedCrossRef
49.
Liu W, Wang Q, Chang J, Bhetuwal A, Bhattarai N, Ni X. Circulatory metabolomics reveals the association of the metabolites with clinical features in the patients with intrahepatic cholestasis of pregnancy. Front Physiol. 2022;13: 848508PubMedPubMedCentralCrossRef
50.
Liu J, Liu L, Chen H. Antenatal taurine supplementation for improving brain ultrastructure in fetal rats with intrauterine growth restriction. Neuroscience. 2011;181:265–270PubMedCrossRef
51.
Shivananjappa MM. Taurine attenuates maternal and embryonic oxidative stress in a streptozotocin-diabetic rat model. Reprod Biomed Online. 2012;24:558–566PubMedCrossRef
52.
Ma Z, Liu Y, Chai L, Jin G, Sun Y, Zhou S, et al. Metabolic changes in bile acids with pregnancy progression and their correlation with perinatal complications in intrahepatic cholestasis of pregnant patients. Sci Rep. 2023;13:1608PubMedPubMedCentralCrossRef
53.
Xu H, Xu Y, Zhao G, et al. The complete change in bile acids and steroids in systematic metabolomics applied to the intrahepatic cholestasis of pregnancy. Mol Omics. 2023;19(5):418–428.PubMedCrossRef
54.
Alnouti Y. Bile Acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009;108:225–246PubMedCrossRef
55.
Geese WJ, Raftogianis RB. Biochemical characterization and tissue distribution of human SULT2B1. Biochem Biophys Res Commun. 2001;288:280–289PubMedCrossRef
56.
Li Y, Zhang X, Chen J, Feng C, He Y, Shao Y, et al. Targeted metabolomics of sulfated bile acids in urine for the diagnosis and grading of intrahepatic cholestasis of pregnancy. Genes Dis. 2018;5:358–366PubMedPubMedCentralCrossRef
57.
Ma L, Zhang X, Pan F, Cui Y, Yang T, Deng L, et al. Urinary metabolomic analysis of intrahepatic cholestasis of pregnancy based on high performance liquid chromatography/mass spectrometry. Clin Chim Acta. 2017;471:292–297PubMedCrossRef
58.
Du Q, Zhang Y, Pan Y, Duan T. Lithocholic acid-induced placental tumor necrosis factor-α upregulation and syncytiotrophoblast cell apoptosis in intrahepatic cholestasis of pregnancy. Hepatol Res. 2014;44:532–541PubMedCrossRef
59.
Chao S, Xiaojun L, Haizhen W, Ludi F, Shaozhen L, Zhiwen S, et al. Lithocholic acid activates mTOR signaling inducing endoplasmic reticulum stress in placenta during intrahepatic cholestasis of pregnancy. Life Sci. 2019;218:300–307PubMedCrossRef
60.
Zheng Q, Shen L, Zhao D, Zhang H, Liang Y, Zhu Y, et al. Metabolic characteristics of plasma bile acids in patients with intrahepatic cholestasis of pregnancy-mass spectrometric study. Metabolomics. 2021;17:93PubMedCrossRef
61.
Spinelli V, Lalloyer F, Baud G, Osto E, Kouach M, Daoudi M, et al. Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. Int J Obes (Lond). 2016;40:1260–1267PubMedCrossRef
62.
Shi Y, Gao Y, Parys MV, Miller D, Milanowski D, Dean B, et al. Definitive profiling of plasma bile acids as potential biomarkers for human liver diseases using UPLC-HRMS. Bioanalysis. 2018;10:917–932PubMedCrossRef
63.
Cui Y, Xu B, Zhang X, He Y, Shao Y, Ding M. Diagnostic and therapeutic profiles of serum bile acids in women with intrahepatic cholestasis of pregnancy-a pseudo-targeted metabolomics study. Clin Chim Acta. 2018;483:135–141PubMedCrossRef
64.
Dong R, Ye N, Zhao S, Wang G, Zhang Y, Wang T, et al. Studies on novel diagnostic and predictive biomarkers of intrahepatic cholestasis of pregnancy through metabolomics and proteomics. Front Immunol. 2021;12: 733225PubMedPubMedCentralCrossRef
65.
Sun X, Qu T, Wang W, Li C, Yang X, He X, et al. Untargeted lipidomics analysis in women with intrahepatic cholestasis of pregnancy: a cross-sectional study. BJOG. 2022;129:880–888PubMedCrossRef
66.
Studer E, Zhou X, Zhao R, Wang Y, Takabe K, Nagahashi M, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology. 2012;55:267–276PubMedCrossRef
67.
Kageyama Y, Ikeda H, Watanabe N, Nagamine M, Kusumoto Y, Yashiro M, et al. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents. Hepatology. 2012;56:1427–1438PubMedCrossRef
68.
Wang Y, Aoki H, Yang J, Peng K, Liu R, Li X, et al. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice. Hepatology. 2017;65:2005–2018PubMedCrossRef
69.
Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744PubMedCrossRef
70.
Abu-Hayyeh S, Papacleovoulou G, Lövgren-Sandblom A, Tahir M, Oduwole O, Jamaludin NA, et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. Hepatology. 2013;57:716–726PubMedCrossRef
71.
Brock WJ, Durham S, Vore M. Characterization of the interaction between estrogen metabolites and taurocholate for uptake into isolated hepatocytes. Lack of correlation between cholestasis and inhibition of taurocholate uptake. J Steroid Biochem. 1984;20:1181–1185PubMedCrossRef
72.
Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Bäckhed HK, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell. 2012;150:470–480PubMedPubMedCentralCrossRef
73.
Li GH, Huang SJ, Li X, Liu XS, Du QL. Response of gut microbiota to serum metabolome changes in intrahepatic cholestasis of pregnant patients. World J Gastroenterol. 2020;26:7338–7351PubMedPubMedCentralCrossRef
74.
Ovadia C, Perdones-Montero A, Fan HM, Mullish BH, McDonald JAK, Papacleovoulou G, et al. Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. Sci Rep. 2020;10:3895PubMedPubMedCentralCrossRef
75.
Ovadia C, Perdones-Montero A, Spagou K, Smith A, Sarafian MH, Gomez-Romero M, et al. Enhanced microbial bile acid deconjugation and impaired ileal uptake in pregnancy repress intestinal regulation of bile acid synthesis. Hepatology. 2019;70:276–293PubMedCrossRef
76.
Li R, Chen X, Liu Z, Chen Y, Liu C, Ye L, et al. Characterization of gut microbiota associated with clinical parameters in intrahepatic cholestasis of pregnancy. BMC Gastroenterol. 2020;20:395PubMedPubMedCentralCrossRef
77.
Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A. 2008;105:13580–13585PubMedPubMedCentralCrossRef
78.
Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, et al. Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial. MBio. 2018;9:10–128CrossRef
79.
Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med. 2013;11:46PubMedPubMedCentralCrossRef
80.
Torres J, Bao X, Goel A, Colombel JF, Pekow J, Jabri B, et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2016;43:790–801PubMedPubMedCentralCrossRef
81.
Zhan Q, Qi X, Weng R, Xi F, Chen Y, Wang Y, et al. Alterations of the human gut microbiota in intrahepatic cholestasis of pregnancy. Front Cell Infect Microbiol. 2021;11: 635680PubMedPubMedCentralCrossRef
82.
Ren SM, Mei L, Huang H, Cao SF, Zhao RH. Zheng PY [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2019;27:369–375PubMed
83.
Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013;4:2384PubMedCrossRef
84.
Lin QX, Huang WW, Shen W, Deng XS, Tang ZY, Chen ZH, et al. Intrahepatic cholestasis of pregnancy increases inflammatory susceptibility in neonatal offspring by modulating gut microbiota. Front Immunol. 2022;13: 889646PubMedPubMedCentralCrossRef
85.
Tang B, Tang L, Li S, Liu S, He J, Li P, et al. Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy. Nat Commun. 2023;14:1305PubMedPubMedCentralCrossRef
86.
Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab. 2018;28:737-749.e734PubMedCrossRef
87.
Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics. 2004;14:91–102PubMedCrossRef
88.
Müllenbach R, Linton KJ, Wiltshire S, Weerasekera N, Chambers J, Elias E, et al. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genet. 2003;40: e70PubMedPubMedCentralCrossRef
89.
Gendrot C, Bacq Y, Brechot MC, Lansac J, Andres C. A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy. J Med Genet. 2003;40: e32PubMedPubMedCentralCrossRef
90.
Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet. 2000;9:1209–1217PubMedCrossRef
91.
Bacq Y, Gendrot C, Perrotin F, Lefrou L, Chrétien S, Vie-Buret V, et al. ABCB4 gene mutations and single-nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy. J Med Genet. 2009;46:711–715PubMedCrossRef
92.
Noor N, Firasat S, Bano N, Afshan K, Gul B, Kaul H. Clinical profile and screening of exon 6 and 14 of ABCB4 gene in obstetric cholestasis patients at a tertiary care hospital in Rawalpindi. Pakistan J Pak Med Assoc. 2021;71:1633–1638PubMed
93.
Liu X, Lai H, Zeng X, Xin S, Nie L, Liang Z, et al. Whole-exome sequencing reveals ANO8 as a genetic risk factor for intrahepatic cholestasis of pregnancy. BMC Pregnancy Childbirth. 2020;20:544PubMedPubMedCentralCrossRef
94.
Bacq Y, le Besco M, Lecuyer AI, Gendrot C, Potin J, Andres CR, et al. Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: results in real-world conditions and factors predictive of response to treatment. Dig Liver Dis. 2017;49:63–69PubMedCrossRef
95.
Batool SS, Dauer M, Weber SN, Liebe R, Lammert F, Reichert MC. Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4. Clin Res Hepatol Gastroenterol. 2022;46: 101800PubMedCrossRef
96.
Floreani A, Caroli D, Lazzari R, Memmo A, Vidali E, Colavito D, et al. Intrahepatic cholestasis of pregnancy: new insights into its pathogenesis. J Matern Fetal Neonatal Med. 2013;26:1410–1415PubMedPubMedCentralCrossRef
97.
Du Q, Pan Y, Zhang Y, Zhang H, Zheng Y, Lu L, et al. Placental gene-expression profiles of intrahepatic cholestasis of pregnancy reveal involvement of multiple molecular pathways in blood vessel formation and inflammation. BMC Med Genomics. 2014;7:42PubMedPubMedCentralCrossRef
Metadata
Title
Intrahepatic cholestasis of pregnancy: insights into pathogenesis and advances in omics studies
Authors
Mi Tang
Liling Xiong
Jianghui Cai
Jinzhu Fu
Hong Liu
Ying Ye
Li Yang
ShaSha Xing
Xiao Yang
Publication date
13-11-2023
Publisher
Springer India
Published in
Hepatology International / Issue 1/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10604-y

Other articles of this Issue 1/2024

Hepatology International 1/2024 Go to the issue

Original Article

Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer

Original Article

Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease

Original Article

Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019

Original Article

Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?

Original Article

Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: a large multicenter cohort study

Editorial

Autophagy and extracellular vesicles in the liver endothelium: friends or foes?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits